This HTML5 document contains 134 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n21http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01212/identifier/chemspider/
n29http://linked.opendata.cz/resource/AHFS/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01212/identifier/chebi/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n18http://linked.opendata.cz/resource/drugbank/dosage/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01212/identifier/wikipedia/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01212/identifier/pharmgkb/
n8http://bio2rdf.org/drugbank:
n13http://linked.opendata.cz/resource/drugbank/drug/DB01212/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB01212/identifier/pubchem-compound/
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01212/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01212/identifier/drugbank/
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n24http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01212/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01212
rdf:type
n3:Drug
n3:description
A broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. [PubChem]
n3:dosage
n18:271B5734-363D-11E5-9242-09173F13E4C5 n18:271B5735-363D-11E5-9242-09173F13E4C5 n18:271B5736-363D-11E5-9242-09173F13E4C5 n18:271B5737-363D-11E5-9242-09173F13E4C5 n18:271B572D-363D-11E5-9242-09173F13E4C5 n18:271B5738-363D-11E5-9242-09173F13E4C5 n18:271B572E-363D-11E5-9242-09173F13E4C5 n18:271B5739-363D-11E5-9242-09173F13E4C5 n18:271B572F-363D-11E5-9242-09173F13E4C5 n18:271B5730-363D-11E5-9242-09173F13E4C5 n18:271B5731-363D-11E5-9242-09173F13E4C5 n18:271B5732-363D-11E5-9242-09173F13E4C5 n18:271B5733-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
5.8-8.7 hours
n3:indication
For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
owl:sameAs
n8:DB01212 n25:DB01212
dcterms:title
Ceftriaxone
adms:identifier
n10:46506458 n11:PA448866 n12:5479530 n13:C06683 n14:0703-0315-03 n15:DB01212 n16:29007 n17:4514885 n19:Ceftriaxone
n3:mechanismOfAction
Ceftriaxone works by inhibiting the mucopeptide synthesis in the bacterial cell wall. The beta-lactam moiety of Ceftriaxone binds to carboxypeptidases, endopeptidases, and transpeptidases in the bacterial cytoplasmic membrane. These enzymes are involved in cell-wall synthesis and cell division. By binding to these enzymes, Ceftriaxone results in the formation of of defective cell walls and cell death.
n3:packager
n4:271B5709-363D-11E5-9242-09173F13E4C5 n4:271B5706-363D-11E5-9242-09173F13E4C5 n4:271B5707-363D-11E5-9242-09173F13E4C5 n4:271B570C-363D-11E5-9242-09173F13E4C5 n4:271B570D-363D-11E5-9242-09173F13E4C5 n4:271B570A-363D-11E5-9242-09173F13E4C5 n4:271B570B-363D-11E5-9242-09173F13E4C5 n4:271B5710-363D-11E5-9242-09173F13E4C5 n4:271B5711-363D-11E5-9242-09173F13E4C5 n4:271B570E-363D-11E5-9242-09173F13E4C5 n4:271B570F-363D-11E5-9242-09173F13E4C5 n4:271B56FD-363D-11E5-9242-09173F13E4C5 n4:271B5700-363D-11E5-9242-09173F13E4C5 n4:271B5701-363D-11E5-9242-09173F13E4C5 n4:271B56FE-363D-11E5-9242-09173F13E4C5 n4:271B56FF-363D-11E5-9242-09173F13E4C5 n4:271B56FA-363D-11E5-9242-09173F13E4C5 n4:271B5717-363D-11E5-9242-09173F13E4C5 n4:271B5718-363D-11E5-9242-09173F13E4C5 n4:271B5715-363D-11E5-9242-09173F13E4C5 n4:271B5716-363D-11E5-9242-09173F13E4C5 n4:271B5713-363D-11E5-9242-09173F13E4C5 n4:271B5714-363D-11E5-9242-09173F13E4C5 n4:271B56FB-363D-11E5-9242-09173F13E4C5 n4:271B56FC-363D-11E5-9242-09173F13E4C5 n4:271B5719-363D-11E5-9242-09173F13E4C5 n4:271B571A-363D-11E5-9242-09173F13E4C5 n4:271B5712-363D-11E5-9242-09173F13E4C5 n4:271B5704-363D-11E5-9242-09173F13E4C5 n4:271B5705-363D-11E5-9242-09173F13E4C5 n4:271B5702-363D-11E5-9242-09173F13E4C5 n4:271B5703-363D-11E5-9242-09173F13E4C5 n4:271B5708-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds.
n3:synonym
Ceftriaxonum Cefatriaxone Ceftriazone Ceftriaxona (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
n3:volumeOfDistribution
* 5.78 to 13.5 L
n26:hasAHFSCode
n29:08-12-06-12
n3:proteinBinding
95%
n3:synthesisReference
Monguzzi Riccardo, Menaspace Silvano, Anzaghi Piergiorgio, "Process for the preparation of ceftriaxone." U.S. Patent US5026843, issued November, 1984.
n22:hasConcept
n23:M0003731
foaf:page
n21:ceftriax.htm n24:ceftriaxone.html
n3:IUPAC-Name
n5:271B573E-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5744-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5743-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5740-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5741-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5742-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B573C-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B573A-363D-11E5-9242-09173F13E4C5 n5:271B573D-363D-11E5-9242-09173F13E4C5 n5:271B5755-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B573B-363D-11E5-9242-09173F13E4C5
n26:hasATCCode
n27:J01DD04
n3:H-Bond-Acceptor-Count
n5:271B574A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B574B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5745-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5746-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5748-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5747-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5749-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Escherichia coli Salmonella typhi Neisseria gonorrhoeae Enteric bacteria and other eubacteria Neisseria meningitidis Haemophilus influenzae
n3:caco2-Permeability
n5:271B5756-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
73384-59-5
n3:category
n3:clearance
* 0.58 - 1.45 L/h [healthy adults receiving 0.15-3 g of CEFTRIAXONE]
n3:containedIn
n6:271B571D-363D-11E5-9242-09173F13E4C5 n6:271B571E-363D-11E5-9242-09173F13E4C5 n6:271B571B-363D-11E5-9242-09173F13E4C5 n6:271B571C-363D-11E5-9242-09173F13E4C5 n6:271B5724-363D-11E5-9242-09173F13E4C5 n6:271B5725-363D-11E5-9242-09173F13E4C5 n6:271B5723-363D-11E5-9242-09173F13E4C5 n6:271B5728-363D-11E5-9242-09173F13E4C5 n6:271B5729-363D-11E5-9242-09173F13E4C5 n6:271B5726-363D-11E5-9242-09173F13E4C5 n6:271B5727-363D-11E5-9242-09173F13E4C5 n6:271B572C-363D-11E5-9242-09173F13E4C5 n6:271B572A-363D-11E5-9242-09173F13E4C5 n6:271B572B-363D-11E5-9242-09173F13E4C5 n6:271B5721-363D-11E5-9242-09173F13E4C5 n6:271B5722-363D-11E5-9242-09173F13E4C5 n6:271B571F-363D-11E5-9242-09173F13E4C5 n6:271B5720-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B5750-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5752-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5753-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B5754-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B574F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B574E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5751-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B573F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B574C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B574D-363D-11E5-9242-09173F13E4C5